Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Consolidated Net Income (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Consolidated Net Income for 13 consecutive years, with $61.0 million as the latest value for Q4 2025.

  • Quarterly Consolidated Net Income rose 96.03% to $61.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $105.8 million through Dec 2025, up 1181.05% year-over-year, with the annual reading at $105.8 million for FY2025, 1181.17% up from the prior year.
  • Consolidated Net Income for Q4 2025 was $61.0 million at Theravance Biopharma, up from $3.6 million in the prior quarter.
  • The five-year high for Consolidated Net Income was $927.1 million in Q3 2022, with the low at -$22.1 million in Q1 2023.
  • Average Consolidated Net Income over 5 years is $53.6 million, with a median of $5.4 million recorded in 2021.
  • The sharpest move saw Consolidated Net Income surged 4400.0% in 2022, then tumbled 318.54% in 2023.
  • Over 5 years, Consolidated Net Income stood at $25.8 million in 2021, then tumbled by 84.9% to $3.9 million in 2022, then plummeted by 318.54% to -$8.5 million in 2023, then soared by 465.46% to $31.1 million in 2024, then soared by 96.03% to $61.0 million in 2025.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at $61.0 million, $3.6 million, and $54.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.